Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Carcinoma, Non-Small-Cell Lung 111Lung Neoplasms 54Hodgkin Disease 22Neoplasm Metastasis 17Recurrence 15Lymphoma 15Triple Negative Breast Neoplasms 14Neoplasms 14Prostatic Neoplasms 10Adenocarcinoma of Lung 10Sarcoma 9Rhabdomyosarcoma 9Uterine Cervical Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Mesothelioma, Malignant 5Breast Neoplasms, Male 5Brain Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4NSCLC 4Multiple Myeloma 4Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

eribulin 1Vinorelbine 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HR+HER2- Breast Cancer × Vinorelbine × Clear all
NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
383 enrolled
Breast

HR+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡